ARE supply chain intelligence for Alexandria Real Estate Equities, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Alexandria Real Estate Equities, Inc. (ARE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALTOS-LABS-INC | ALTOS-LABS-INC | 90% | Annual rental revenue and RSF include 100% of each property managed by us in North America. |
| AMGEN-INC | AMGEN-INC | 90% | Annual rental revenue and RSF include 100% of each property managed by us in North America. |
| VAXCYTE-INC | VAXCYTE-INC | 90% | Annual rental revenue and RSF include 100% of each property managed by us in North America. |
| BRNS | Barinthus Biotherapeutics plc | 72% | Reciprocal relationship from BRNS graph: Reciprocal relationship from ARE graph: Reciprocal relationship from BRNS graph: Reciprocal relationship from ARE graph: Reciprocal relationship from BRNS gra… |
| EIKN | EIKN | 72% | Item 2 for additional details, including our methodologies of calculating annual rental revenue from unconsolidated real estate joint ventures and average market capitalization, respectively. (1) Bas… |
| EIKN | EIKN | 72% | Reciprocal relationship from EIKN graph: Reciprocal relationship from ARE graph: Item 2 for additional details, including our methodologies of calculating annual rental revenue from unconsolidated re… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from ARE graph: Reciprocal relationship from MRK graph: Reciprocal relationship from ARE graph: Reciprocal relationship from MRK graph:… |
| MRK | Merck & Co., Inc. | 72% | Item 2 for additional details, including our methodologies of calculating annual rental revenue from unconsolidated real estate joint ventures and average market capitalization, respectively. (1) Bas… |
| NVSEF | Novartis AG | 72% | er Technologies, Inc. 56.5 (4) 1,009,188 27,865 1.5 Baa1 BBB $ 178.6 10 Boston Children's Hospital 11.0 309,231 26,294 1.4 Aa2 AA $ — 11 Novartis AG 2.2 (5) 321,743 25,111 1.4 Aa3 AA- $ 273.6 12 Sano… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from ARE graph: er Technologies, Inc. 56.5 (4) 1,009,188 27,865 1.5 Baa1 BBB $ 178.6 10 Boston Children's Hospital 11.0 309,231 26,29… |
| SNYNF | Sanofi | 72% | er Technologies, Inc. 56.5 (4) 1,009,188 27,865 1.5 Baa1 BBB $ 178.6 10 Boston Children's Hospital 11.0 309,231 26,294 1.4 Aa2 AA $ — 11 Novartis AG 2.2 (5) 321,743 25,111 1.4 Aa3 AA- $ 273.6 12 Sano… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ARE graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ARE graph: Reciprocal relationship from SNYNF … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ARE-DEBT | Debt stack $12.8B | 90% | Market cache reports total debt of $12.8B. |
| ARE-DEBT-7188 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2010-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ARE-OWNER-MAREX-GROUP-PLC | Marex Group plc | 95% | 13F/ownership overlay lists Marex Group plc; shares held 30,000; value $197.6M; as of 2026-03-31. |
| ARE-OWNER-BARCLAYS-PLC | BARCLAYS PLC | 95% | 13F/ownership overlay lists BARCLAYS PLC; shares held 837,813; value $4.4B; as of 2026-03-31. |
| ARE-OWNER-ESSENTIAL-PARTNERS-LLC | Essential Partners LLC | 95% | 13F/ownership overlay lists Essential Partners LLC; shares held 225; value $70,000; as of 2026-03-31. |
| ARE-OWNER-GOLDMAN-SACHS-GROUP-INC | GOLDMAN SACHS GROUP INC | 95% | 13F/ownership overlay lists GOLDMAN SACHS GROUP INC; shares held 146,219; value $14.6M; as of 2026-03-31. |
| ARE-OWNER-ROCKEFELLER-CAPITAL-MANAGEMENT-L-P | Rockefeller Capital Management L.P. | 95% | 13F/ownership overlay lists Rockefeller Capital Management L.P.; shares held 241,897; value $24.2M; as of 2026-03-31. |
| ARE-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 95% | 13F/ownership overlay lists MORGAN STANLEY; shares held 891,789; ownership 0.51%; value $449.3M; as of 2026-03-31. |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Woronoff Michael A | 10% Owner | buy | 1400 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Klein Richard Hunter | Director | buy | 112 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Klein Richard Hunter | Director | buy | 112 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Nelson Jesse J. | EVP - RMD | option_exercise | 43085 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Boss Michael E. | Co-Regional Market Director | buy | 21543 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Dean Gary D. | EVP, Real Estate Legal Affairs | sell | 16157 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Gavinet Andres | Chief Accounting Officer | buy | 32314 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Thomas Gregory Calvin | EVP - CTO | buy | 10772 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Hash Steve | 10% Owner | buy | 343 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Hash Steve | 10% Owner | buy | 343 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Moglia Peter M | Chief Executive Officer | sell | 1067 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Kuhn Hallie E. | EVP - Cap Market & Co-Lead -LS | buy | 21543 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Lee Orraparn C. | EVP - Accounting | buy | 21543 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Stevens Blake L. | Regional Market Director | buy | 10772 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Gossett Bret E. | EVP - Co-RMD | buy | 11849 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Clem Jackie B. | General Counsel & Secretary | option_exercise | 21543 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Hakman Joseph | Co-Chief Operating Officer | option_exercise | 32314 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Alsbrook Madeleine Thorp | EVP - Talent Management | buy | 16157 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Boss Michael E. | Co-Regional Market Director | buy | 21543 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Mitchell Joshua J. | Regional Market Director | buy | 12926 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Dean Gary D. | EVP, Real Estate Legal Affairs | sell | 16157 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Gavinet Andres | Chief Accounting Officer | buy | 32314 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | Thomas Gregory Calvin | EVP - CTO | buy | 10772 shares |
| ARE | Alexandria Real Estate Equities, Inc. | 82% | McGrath Sheila K. | Director | buy | 129 shares |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BRNS | Barinthus Biotherapeutics plc | 100.00 | 1 | ['customer'] |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 |